Alok Srivastava/LinkedIn, Khaled Musallam/LinkedIn
May 6, 2026, 02:23
Khaled Musallam: When the Worlds of Thalassemia and Hemophilia Converge
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared a post on LinkedIn:
“When the worlds of thalassemia and hemophilia converge, impactful advances are inevitable.
Delighted to welcome Prof Alok Srivastava as Visiting Professor, Consultant Hematologist, and Deputy Chief of Cell and Gene Therapy and Hematology at Burjeel Cancer Institute.
Excited for what lies ahead as we build robust services and bring forward innovative therapies for patients with blood disorders.”
More posts featuring Khaled Musallam on Hemostasis Today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy